KR20160132115A - 면역 반응을 유도하기 위한 신규한 방법 - Google Patents

면역 반응을 유도하기 위한 신규한 방법 Download PDF

Info

Publication number
KR20160132115A
KR20160132115A KR1020167029523A KR20167029523A KR20160132115A KR 20160132115 A KR20160132115 A KR 20160132115A KR 1020167029523 A KR1020167029523 A KR 1020167029523A KR 20167029523 A KR20167029523 A KR 20167029523A KR 20160132115 A KR20160132115 A KR 20160132115A
Authority
KR
South Korea
Prior art keywords
adjuvant
composition
ala
months
rts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167029523A
Other languages
English (en)
Korean (ko)
Inventor
윌리엄 리플레이 주니어 발로우
아노드 미카엘 디디에로랑
로버트 게리트 반 더 모스트
Original Assignee
글락소스미스클라인 바이오로지칼즈 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 바이오로지칼즈 에스.에이. filed Critical 글락소스미스클라인 바이오로지칼즈 에스.에이.
Priority to KR1020237017095A priority Critical patent/KR102762440B1/ko
Publication of KR20160132115A publication Critical patent/KR20160132115A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020167029523A 2014-04-02 2015-04-02 면역 반응을 유도하기 위한 신규한 방법 Ceased KR20160132115A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237017095A KR102762440B1 (ko) 2014-04-02 2015-04-02 면역 반응을 유도하기 위한 신규한 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1405921.6A GB201405921D0 (en) 2014-04-02 2014-04-02 Novel methods for inducing an immune response
GB1405921.6 2014-04-02
PCT/EP2015/057424 WO2015150568A1 (en) 2014-04-02 2015-04-02 Novel methods for inducing an immune response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237017095A Division KR102762440B1 (ko) 2014-04-02 2015-04-02 면역 반응을 유도하기 위한 신규한 방법

Publications (1)

Publication Number Publication Date
KR20160132115A true KR20160132115A (ko) 2016-11-16

Family

ID=50737873

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167029523A Ceased KR20160132115A (ko) 2014-04-02 2015-04-02 면역 반응을 유도하기 위한 신규한 방법
KR1020237017095A Active KR102762440B1 (ko) 2014-04-02 2015-04-02 면역 반응을 유도하기 위한 신규한 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237017095A Active KR102762440B1 (ko) 2014-04-02 2015-04-02 면역 반응을 유도하기 위한 신규한 방법

Country Status (18)

Country Link
US (3) US10688168B2 (enExample)
EP (2) EP3125930B1 (enExample)
JP (2) JP6645982B2 (enExample)
KR (2) KR20160132115A (enExample)
CN (2) CN106456739A (enExample)
AR (1) AR099960A1 (enExample)
AU (1) AU2015239025B2 (enExample)
BE (1) BE1022355B1 (enExample)
BR (2) BR112016022463A2 (enExample)
CA (2) CA2943007C (enExample)
EA (1) EA037405B1 (enExample)
ES (2) ES2961840T3 (enExample)
GB (1) GB201405921D0 (enExample)
IL (1) IL247493B (enExample)
MX (3) MX2016012982A (enExample)
SG (1) SG11201607086QA (enExample)
WO (2) WO2015150567A1 (enExample)
ZA (1) ZA201605955B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201621686D0 (en) * 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB2600652B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel compositions
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
US12569553B2 (en) 2020-03-09 2026-03-10 Dynavax Technologies Corporation Shingles vaccines comprising a TLR9 agonist
CN112198318B (zh) * 2020-07-15 2021-07-20 南京岚煜生物科技有限公司 抗体标准品赋值和抗体检测试剂最低检出限确定的方法
CN114272369A (zh) * 2020-09-27 2022-04-05 中国科学院微生物研究所 用于预防水痘-带状疱疹病毒的mRNA疫苗组合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US152200A (en) * 1874-06-16 Improvement in garters
US1002607A (en) * 1905-08-28 1911-09-05 John Willard Taylor Paper pulley.
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US8232255B2 (en) 2002-10-23 2012-07-31 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
BRPI0518146A (pt) 2004-10-14 2008-10-28 Crucell Holland Bv kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária
PT2426141E (pt) * 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2087128A4 (en) * 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
CN103550764A (zh) * 2007-03-02 2014-02-05 葛兰素史密丝克莱恩生物有限公司 疫苗组合物及其在刺激免疫反应中的用途
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
NO2315597T3 (enExample) * 2008-07-25 2018-01-20
EP2315773B1 (en) * 2008-07-25 2016-08-24 GlaxoSmithKline Biologicals S.A. Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis
HRP20181353T1 (hr) * 2008-07-25 2018-10-19 Glaxosmithkline Biologicals S.A. Tuberkulozni protein rv2386c, njegovi pripravci i upotreba
LT2528621T (lt) * 2010-01-27 2016-12-12 Glaxosmithkline Biologicals S.A. Modifikuoti tuberkuliozės antigenai
SG190937A1 (en) 2010-12-14 2013-07-31 Glaxosmithkline Biolog Sa Mycobacterium antigenic composition
WO2015126930A2 (en) * 2014-02-18 2015-08-27 Stc.Unm Booster drug therapy for mycobacterium infections
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
WO2015161853A1 (en) * 2014-04-24 2015-10-29 Statens Serum Institut New m.tuberculosis vaccines
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response

Also Published As

Publication number Publication date
US20200306353A1 (en) 2020-10-01
JP2017511324A (ja) 2017-04-20
ZA201605955B (en) 2019-04-24
ES2853773T3 (es) 2021-09-17
CA2943007A1 (en) 2015-10-08
CA2943711A1 (en) 2015-10-08
EP3125929B1 (en) 2023-11-01
IL247493A0 (en) 2016-11-30
CN106456739A (zh) 2017-02-22
CN106456738B (zh) 2021-06-29
AU2015239025B2 (en) 2018-01-25
JP6655549B2 (ja) 2020-02-26
WO2015150567A1 (en) 2015-10-08
AR099960A1 (es) 2016-08-31
JP6645982B2 (ja) 2020-02-14
BE1022355B1 (fr) 2016-03-26
CA2943007C (en) 2024-01-09
ES2961840T3 (es) 2024-03-14
MX2022013912A (es) 2022-12-13
US11951161B2 (en) 2024-04-09
EP3125929A1 (en) 2017-02-08
US20170136110A1 (en) 2017-05-18
KR20230075525A (ko) 2023-05-31
CN106456738A (zh) 2017-02-22
MX2016012982A (es) 2016-12-07
WO2015150568A1 (en) 2015-10-08
BE1022355A1 (fr) 2016-02-16
EP3125930B1 (en) 2020-12-02
BR112016022463A2 (pt) 2017-10-10
KR102762440B1 (ko) 2025-02-03
AU2015239025A1 (en) 2016-09-22
JP2017511327A (ja) 2017-04-20
EP3125930A1 (en) 2017-02-08
EA037405B1 (ru) 2021-03-25
US10624961B2 (en) 2020-04-21
BR112016022787A2 (pt) 2018-03-27
GB201405921D0 (en) 2014-05-14
MX2016012932A (es) 2016-12-07
EP3125929C0 (en) 2023-11-01
US10688168B2 (en) 2020-06-23
IL247493B (en) 2022-08-01
SG11201607086QA (en) 2016-09-29
EP3125929B8 (en) 2023-12-27
US20170112914A1 (en) 2017-04-27
EA201691638A1 (ru) 2017-04-28

Similar Documents

Publication Publication Date Title
US11951161B2 (en) Methods for inducing an immune response
US11679153B2 (en) Methods for inducing an immune response
JP5486802B2 (ja) 抗マラリアワクチン
BE1022373B1 (fr) Nouveaux vaccins antipaludeens
US11583578B2 (en) Plasmodium falciparum recombinanr xiexumapoeozoite protein compositions and method for vaccine delivery
WO2016046113A1 (en) Novel methods for inducing an immune response

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161021

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200326

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211117

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220620

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211117

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220620

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220217

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200326

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20221221

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20221117

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20220620

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220217

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20211117

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200326

X601 Decision of rejection after re-examination